CS 17938
Alternative Names: CS-17938Latest Information Update: 28 Sep 2024
Price :
$50 *
At a glance
- Originator Chipscreen Biosciences
- Class Antineoplastics; Small molecules
- Mechanism of Action Immunologic cytotoxicity; Programmed cell death 1 receptor antagonists; Programmed cell death-1 ligand-1 inhibitors; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Sep 2024 No recent reports of development identified for preclinical development in Cancer in China
- 28 Aug 2020 Preclinical trials in Cancer in China (unspecified route) before August 2020 (Biosciences pipeline, August 2020)